The FDA approves Axiron, Eli Lilly's (LLY) topical solution for testosterone replacement therapy...

|About: Eli Lilly and Company (LLY)|By:, SA News Editor

The FDA approves Axiron, Eli Lilly's (LLY) topical solution for testosterone replacement therapy in men. The U.S. testosterone market, estimated at $1B, is set to grow 20% annually. Acrux (ARUXF.PK), Lilly's Australian partner on the drug, rose 9.1% in Aussie trading.